Ironwood Pharmaceuticals (IRWD) Competitors $1.27 -0.10 (-7.30%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$1.33 +0.06 (+4.72%) As of 09/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IRWD vs. ABBV, GERN, RIGL, MYGN, VSTM, XOMA, EBS, LXRX, VNDA, and CBIOShould you be buying Ironwood Pharmaceuticals stock or one of its competitors? The main competitors of Ironwood Pharmaceuticals include AbbVie (ABBV), Geron (GERN), Rigel Pharmaceuticals (RIGL), Myriad Genetics (MYGN), Verastem (VSTM), XOMA Royalty (XOMA), Emergent Biosolutions (EBS), Lexicon Pharmaceuticals (LXRX), Vanda Pharmaceuticals (VNDA), and Crescent Biopharma (CBIO). These companies are all part of the "medical" sector. Ironwood Pharmaceuticals vs. Its Competitors AbbVie Geron Rigel Pharmaceuticals Myriad Genetics Verastem XOMA Royalty Emergent Biosolutions Lexicon Pharmaceuticals Vanda Pharmaceuticals Crescent Biopharma Ironwood Pharmaceuticals (NASDAQ:IRWD) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings. Is IRWD or ABBV more profitable? AbbVie has a net margin of 6.45% compared to Ironwood Pharmaceuticals' net margin of -2.25%. AbbVie's return on equity of 699.66% beat Ironwood Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ironwood Pharmaceuticals-2.25% -2.46% 2.19% AbbVie 6.45%699.66%13.64% Which has more volatility and risk, IRWD or ABBV? Ironwood Pharmaceuticals has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Do institutionals & insiders hold more shares of IRWD or ABBV? 70.2% of AbbVie shares are owned by institutional investors. 12.7% of Ironwood Pharmaceuticals shares are owned by insiders. Comparatively, 0.3% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer IRWD or ABBV? In the previous week, AbbVie had 104 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 105 mentions for AbbVie and 1 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 1.89 beat AbbVie's score of 1.30 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Ironwood Pharmaceuticals Very Positive AbbVie Positive Which has better valuation and earnings, IRWD or ABBV? AbbVie has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIronwood Pharmaceuticals$351.41M0.59$880K-$0.05-25.40AbbVie$56.33B6.84$4.28B$2.10103.92 Do analysts prefer IRWD or ABBV? Ironwood Pharmaceuticals presently has a consensus price target of $4.94, suggesting a potential upside of 288.98%. AbbVie has a consensus price target of $223.45, suggesting a potential upside of 2.39%. Given Ironwood Pharmaceuticals' higher probable upside, analysts plainly believe Ironwood Pharmaceuticals is more favorable than AbbVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ironwood Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14AbbVie 0 Sell rating(s) 6 Hold rating(s) 17 Buy rating(s) 4 Strong Buy rating(s) 2.93 SummaryAbbVie beats Ironwood Pharmaceuticals on 14 of the 17 factors compared between the two stocks. Get Ironwood Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRWD vs. The Competition Export to ExcelMetricIronwood PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$222.54M$2.55B$5.74B$10.39BDividend YieldN/A54.21%5.75%4.64%P/E Ratio-25.3923.2675.7726.11Price / Sales0.59716.05544.59124.93Price / Cash27.70176.2437.5461.24Price / Book-0.685.1412.876.30Net Income$880K$32.95M$3.29B$271.03M7 Day Performance-9.93%1.15%0.26%-0.14%1 Month PerformanceN/A4.94%2.85%5.82%1 Year Performance-68.72%0.55%65.65%27.63% Ironwood Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRWDIronwood Pharmaceuticals4.2994 of 5 stars$1.27-7.3%$4.94+289.0%-67.7%$222.54M$351.41M-25.39220Positive NewsABBVAbbVie4.8086 of 5 stars$217.92-0.2%$218.76+0.4%+14.1%$385.71B$56.33B103.7755,000Trending NewsAnalyst RevisionGERNGeron2.993 of 5 stars$1.27flat$3.79+198.1%-71.8%$810.28M$76.99M-9.7770RIGLRigel Pharmaceuticals3.3953 of 5 stars$37.30-1.7%$38.20+2.4%+78.8%$680.90M$179.28M6.89160Positive NewsMYGNMyriad Genetics3.2503 of 5 stars$7.31+1.0%$12.45+70.4%-70.3%$673.64M$837.60M-1.712,700Positive NewsVSTMVerastem2.5481 of 5 stars$9.82+1.0%$13.29+35.3%+227.4%$598.22M$10K-2.9950XOMAXOMA Royalty4.2614 of 5 stars$37.86+1.2%$69.50+83.6%+36.8%$452.32M$28.49M-24.4310Insider TradeGap DownEBSEmergent Biosolutions4.6751 of 5 stars$7.98-2.0%$13.50+69.2%+47.2%$434.28M$1.04B3.262,420LXRXLexicon Pharmaceuticals2.0842 of 5 stars$1.12-2.6%$3.23+187.9%-11.3%$417.91M$31.08M-3.39140VNDAVanda Pharmaceuticals4.0726 of 5 stars$4.38-2.9%$16.50+276.7%-0.4%$266.49M$198.77M-3.88290News CoveragePositive NewsCBIOCrescent Biopharma4.316 of 5 stars$12.22-2.2%$25.60+109.5%N/A$244.18M$10K-0.3550 Related Companies and Tools Related Companies AbbVie Alternatives Geron Alternatives Rigel Pharmaceuticals Alternatives Myriad Genetics Alternatives Verastem Alternatives XOMA Royalty Alternatives Emergent Biosolutions Alternatives Lexicon Pharmaceuticals Alternatives Vanda Pharmaceuticals Alternatives Crescent Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRWD) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredChina Targets MAGA In Stealth Trade War TacticsChina is deliberately targeting the economic backbone of conservative America - The very industries that supp...Goldco Precious Metals | SponsoredCollege grad makes $64,000 a monthNothing hurts like a missed opportunity... And with AI stocks like Nvidia, Palantir, and Oracle continuing...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IRWD Stock Alerts